Possibilities of radionuclide diagnostics of Her2-positive breast cancer using technetium-99m-labeled target molecules: the first experience of clinical use
Background. The main purpose of the Her2/neu status determination in clinical practice is to determine the indications for the appointment of targeted therapy. The main methods for detecting the Her2/neu status are the immunohistochemical method (IHC) and the fluorescence in situ hybridization (FISH...
Saved in:
Main Authors: | O. D. Bragina, V. I. Chernov, E. Yu. Garbukov, A. V. Doroshenko, A. G. Vorobyeva, A. M. Orlova, V. M. Tolmachev |
---|---|
Format: | Article |
Language: | English |
Published: |
Siberian State Medical University (Tomsk)
2021-04-01
|
Series: | Бюллетень сибирской медицины |
Subjects: | |
Online Access: | https://bulletin.ssmu.ru/jour/article/view/4270 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comparative Analysis of the Clinical Use of 99mTechnetium-Labeled Recombinant Target Molecules in Different Dosages for the Radionuclide Diagnosis of Her2-Positive Breast Cancer
by: O. D. Bragina, et al.
Published: (2021-06-01) -
Possibilities of predicting the HER2 / neu status in a primary tumor in breast cancer patients using <sup>99m</sup>Tc-DARPinG3
by: O. D. Bragina, et al.
Published: (2023-01-01) -
Clinical possibilities of HER2-positive breast cancer diagnosis using alternative scaffold proteins
by: O. D. Bragina, et al.
Published: (2022-10-01) -
Alternative scaffolds in radionuclide diagnosis of malignancies
by: O. D. Bragina, et al.
Published: (2019-10-01) -
EVALUATION OF EXTENT OF BREAST CANCER IN A PATIENT WITH HER2/NEU OVEREXPRESSION USING A RADIOPHARMACEUTICAL BASED ON TECHNETIUM-99M-LABELED TARGET MOLECULES (CASE REPORT)
by: O. D. Bragina, et al.
Published: (2021-10-01)